Actionable Strategies in Community Oncology to Achieve Equity in Triple-Negative Breast Cancer
This Grand Rounds series focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events.
Join our expert faculty for this 60-minute program that will help you understand the complexity of TNBC and the far-reaching racial disparities intrinsic to the disease.
Physicians, physician associates (PAs), nurse practitioners (NPs), pharmacists, nurses specializing in oncology and practice in a community setting.
- Employ strategies to promote equitable care and outcomes for all patients with TNBC.
- Evaluate clinical trial data for ADCs as part of the evolving and expanding TNBC treatment calculus, including recent FDA approvals and updated guideline recommendations.
- Incorporate evidence-based treatment plans with an emphasis on the placement of novel therapeutics as part of equitable care for patients with TNBC.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Gilead Sciences, Inc.
5 min Introductions
15 min Delineating the Disparity in Triple-negative Breast Cancer (TNBC): The Interface of Disease-state Complexity and Social Inequity
15 min Demystifying Antibody-drug Conjugates (ADCs): Practical Approaches to Embracing Change in the Evolving TNBC Paradigm
15 min Closing the TNBC Outcomes Chasm: Case-based Challenges for the Community Oncologist and Their Interprofessional Team
5 min SMART Goals/Conclusions
5 min Q&A
Sonya Reid, MD, MPH
Assistant Professor of Medicine
Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Sara Tolaney, MD, MPH–reports the following financial relationships: Consultant to 4D pharma plc; Aadi Biosciences; Arch Therapeutics, Inc.; AstraZeneca; Athenex, Inc.; Bayer; BeyondSpring Inc.; Blueprint Medicines Corporation; Bristol Myers Squibb Company; Certara, Inc.; Chugai Pharma USA, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Eli Lilly and Company; Ellipses Pharma; Genentech, Inc./Roche; Gilead Sciences, Inc.; Infinity Therapeutics; Menarini/Stemline Therapeutics, Inc.; Merck & Co., Inc.; Mersana therapeutics; Myovant Sciences; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc.; OncoSec Medical Inc.; OncXerna Therapeutics, Inc.; Pfizer Inc.; Sanofi; Seattle Genetics; Inc.; Reveal Genomics; Umoja Biopharma; Zentalis Pharmaceuticals; Zetagen; and Zymeworks Inc. Research Support (paid to institution) from AstraZeneca; Bristol Myers Squibb Company; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./Roche; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString; Nektar; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi and Seattle Genetics, Inc.
Rita Nanda, MD–reports the following financial relationships: Advisory Board: AstraZeneca; BeyondSpring Inc.; Daiichi Sankyo, Inc.; Fujifilm; GE Pharmaceuticals; Gilead Sciences, Inc.; Infinity Pharmaceuticals, Inc.; iTeos Therapeutics; MacroGenics, Inc; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; OncoSsec; Pifzer Inc.; Sanofi; and Seagen Inc.; Stemline Therapeutics, Inc. Research Support: Arvinas; AstraZeneca; Celgene Corporation; Corcept; Genentec, Inc./Roche; Gilead Sciences, Inc./Immunomedics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; OncoSec; Pfizer Inc.; Relay Therapeutics; Seattle Genetics, Inc.; Sun Pharma; and Taiho Oncology, Inc.
Sonya Reid, MD, MPH–disclosures to come
Information to come
Katherine A. Lee, PharmD, MPH–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-23-006-L01-P)
This activity is designated for 1.0 contact hour.
- 1.00 AAPA Category I CME
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 IPCE
- 1.00 Participation